KALA BIO, INC. Net Fee Amt
KALA BIO, INC. (KALA) had Net Fee Amt of $3.06 thousand as of 2026-05-07, per its S-3 filed 2026-05-07.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-07
- 2026-05-07: Net Fee Amt $3.06K.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-07 | $3.06K S-3 · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |